The Science, Policy, and Potential of Cell and Gene Therapies

Wednesday, December 4, 2019

Speakers

Rena Conti	Boston University Institute for Health System Innovation and Policy, Associate Research Director of Biopharma and Public Policy rconti@bu.edu
R. John Glasspool	MIT Center for Biomedical Innovation: NEWDIGS, Financing and Reimbursement of Cures in the US (FoCUS) Project, Senior Advisor; Anthos Therapeutics, CEO r.john.glasspool@gmail.com
Joanne Kurtzberg	Duke University School of Medicine, Director of the Marcus Center for Cellular Cures (MC3) Kurtz001@mc.duke.edu
Gillian Woollett	Avalere Health, Principal Research Scientist gwoollett@avalere.com

Experts and Analysts

Peter Bach	Memorial Sloan Kettering Cancer Center, Director of the Center for Health Policy and Outcomes bachp@mskcc.org
Thomas Barker	Foley Hoag, LLP, Partner and Co-Chair of Healthcare Practice tbarker@foleyhoag.com
Justin Bekelman	Penn Center for Cancer Care Innovation at the Abramson Cancer Center, Director; University of Pennsylvania Perelman School of Medicine, Associate Professor Bekelman@upenn.edu
Robert W. Dubois	National Pharmaceutical Council, Chief Science Officer & Executive Vice President rdubois@npcnow.org
Lisa Bo Feng	Cystic Fibrosis Foundation, Senior Director of Policy and Advocacy lfeng@cff.org
Jennifer Bright	Momentum Health Strategies, Executive Director of Innovation and Value Initiative jennifer@momentumhealthstrategies.com
Sarah Emond	Institute for Clinical and Economic Review, Executive Vice President and Chief Operating Officer semond@icer-review.org
Andrew Hu	Patient-Centered Outcomes Research Institute, Director of Policy and Government Relations ahu@pcori.org
Karen Katz	MIT Center for Biomedical Innovation: NEWDIGS, Financing and Reimbursement of Cures in the US (FoCUS) Project, Director kkatz@mit.edu
Eleanor M. Perfetto	National Health Council, Executive Vice President of Strategic Initiatives eperfetto@nhcouncil.org
Morgan Romine	Duke Margolis Center for Health Policy, Policy Fellow for Strategic Engagement morgan.romine@duke.edu
Jeremy Sharp	Waxman Strategies, Senior Vice President jeremy@waxmanstrategies.com
Zachary Zalewski	Avalere Health, Consultant ZZalewski@avalere.com

Government

Anna Abram	FDA, Deputy Commissioner for Policy, Planning, Legislation and Analysis Anna.Abram@fda.hhs.gov
John Coster	CMS, Director of Division of Pharmacy at Center for Medicaid and Chip Services John.Coster@cms.hhs.gov
Molly Morein	Medicare Payment Advisory Commission, Special Assistant mmorein@medpac.gov
Matt Salo	National Association of Medicaid Directors, Executive Director matt.salo@medicaiddirectors.org
Anne Schwartz	Medicaid and CHIP Payment and Access Commission, Executive Director Anne.Schwartz@macpac.gov
Elad Sharon	National Institutes of Health, Senior Investigator in the Investigational Drug Branch of the National Cancer Institute sharone@mail.nih.gov

Stakeholders

Jeremy Allen	Spark Therapeutics, Inc., Head of Government Affairs Jeremy.allen@sparktx.com
Holly Campbell	Pharmaceutical Research and Manufacturers of America, Deputy Vice President of Public Affairs hcampbell@phrma.org
Erin Darling	Merck, Associate Vice President of Federal Policy and Government Relations Erin.darling@merck.com
Shari Erickson	American College of Physicians, Vice President of Government Affairs serickson@acponline.org
Betsy Foss-Campbell	American Society of Gene and Cell Therapy, Director of Policy and Advocacy bfoss@asgct.org
Janet Lambert	Alliance for Regenerative Medicine, CEO jlambert@alliancerm.org
Lisa Mostovoy	Blue Cross Blue Shield Association, Executive Director of Clinical Pharmacy Services Lisa.Mostovoy@bcbsa.com
Murray Ross	Kaiser Permanente, Government Relations & Institute for Health Policy murray.ross@kp.org
Heidi Rosvold-Brenholtz	Healthy Women, Senior Vice President for Strategic Engagement of Policy and Science heidi@healthywomen.org
Mark Skinner	Institute for Policy Advancement Ltd., President & CEO; Former Head of the National Hemophilia Foundation mskinner@ipaltd.com
Gretchen C. Wartman	National Minority Quality Forum, Vice President for Policy and Program gwartman@nmqf.org
Steven Wojcik	National Business Group on Health, Vice President of Public Policy wojcik@businessgrouphealth.org

Jun24

past webinar

COVID-19 Webinar Series Session 20 - Tensions, Tradeoffs, and Takeaways: What’s at Stake for America 100 Days into the Pandemic  and Where We Go From Here

Just over 100 days have passed since the COVID-19 pandemic was declared a national emergency on March 13, 2020. The pandemic has led to sweeping ramifications throughout the American economy and society as a whole. During this interactive discussion, three preeminent health policy leaders will examine the lessons learned three months into the crisis and lay out considerations for decision-makers as they work to stem the tide of the pandemic and build a more resilient health care system.

Jun19

past webinar

COVID-19 Webinar Series Session 19 - Advancing Mental Health During the Pandemic and Beyond

During this webinar, panelists addressed the following learning goals: the short- and long-term impact of COVID-19 on mental health and well being; evidence-based interventions and promising technology to reach people where they are and improve outcomes; and sustainable solutions to address the mental health impact of COVID-19 and advance access to behavioral health services beyond the pandemic.

Jun16

past webinar

COVID-19 Webinar Series Session 18 - Health Inequities: Addressing the Disease Burden in Black, Indigenous, and People of Color Communities

During this webinar, speakers examined the following learning goals: the disproportionate impact of COVID-19 on Black, Indigenous, and People of Color communities in the U.S.; the drivers of these disparities; and short- and long-term policy options to advance equity and improve COVID-19 outcomes.